loading page

Mini-Hyper CVD+CRIB (Condensed Rituximab, Inotuzumab Ozogamicin, and Blinatumomab) for Refractory Pediatric B-ALL
  • +2
  • David McCall,
  • Elias Jabbour,
  • Michael Roth,
  • Cesar Nunez,
  • Branko Cuglievan
David McCall
Department of Pediatrics The University of Texas MD Anderson Cancer Center Houston Texas

Corresponding Author:[email protected]

Author Profile
Elias Jabbour
The University of Texas MD Anderson Cancer Center Department of Leukemia
Author Profile
Michael Roth
Department of Pediatrics The University of Texas MD Anderson Cancer Center Houston Texas
Author Profile
Cesar Nunez
Department of Pediatrics The University of Texas MD Anderson Cancer Center Houston Texas
Author Profile
Branko Cuglievan
Department of Pediatrics The University of Texas MD Anderson Cancer Center Houston Texas
Author Profile

Abstract

Relapsed or refractive pediatric B-Acute Lymphoblastic Leukemia (B-ALL) patients have high rates of toxicities and relapse, and novel therapy is needed. We present a case of a 5-year-old male with high-risk B-ALL that was refractive to several re-induction regimens. He was put into MRD-negative remission after re-induction with chemotherapy plus overlapping rituximab, inotuzumab ozogamicin and blinatumomab, termed Mini-Hyper-CVD plus CRIB. This was well tolerated, and he received his transplant and engrafted with no significant infections, toxicities, or sinusoidal obstruction syndrome. This is the first reported use in pediatrics of a condensed sequential immunotherapy/chemotherapy regimen in a pediatric leukemia patient.
14 Jun 2022Submitted to Pediatric Blood & Cancer
14 Jun 2022Submission Checks Completed
14 Jun 2022Assigned to Editor
21 Jun 2022Reviewer(s) Assigned
21 Jul 2022Review(s) Completed, Editorial Evaluation Pending
22 Jul 2022Editorial Decision: Revise Minor
01 Aug 2022Submission Checks Completed
01 Aug 2022Assigned to Editor
01 Aug 20221st Revision Received
02 Aug 2022Review(s) Completed, Editorial Evaluation Pending
02 Aug 2022Editorial Decision: Accept